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ABSTRACT 
Objective: A simple, direct and accurate spectrophotometric method has been developed for the determination of cefpodoxime proxetil (CEFP) in 
pure and pharmaceutical formulations by complex formation with bromothymol blue (BTB).  
Methods: The method involves the formation of yellow ion-pair complexes between BTB reagent and CEFP in chloroform. The two formed 
complexes ([CEFP]: [BTB] and [CEFP]: [BTB]2) have maximum absorption at λmax 422 nm. The proposed method was validated for specificity, 
linearity, precision and accuracy, repeatability, sensitivity (LOD and LOQ) and robustness with an average recovery of 99.0-101.4%. 
Results: The formed complex ([CEFP]: [BTB]2) was measured against the reagent blank prepared in the same manner. Variables were studied in order 
to optimize the reaction conditions. Molar absorptivity (ε) for two complexes were 8100 and 12600  L. mol-1. cm-1, respectively. Beer’s law was obeyed in 
the concentration range of 0.5576-55.760 μg/ml in the present of 1x10-3 mol/l of BTB with good correlation coefficient (R2= 0.9995). The relative 
standard deviation did not exceed 4.7%. The limit of detection (LOD) and the limit of quantification (LOQ) were 0.088 and 0.27 μg/ml, respectively.  
Conclusion: The developed method is applicable for the determination of CEFP in pure and different dosage forms with the average assay of 
marketed formulations 99.5 to 103.2%, and the results are in good agreement with those obtained by the RP-HPLC reference method.  
Keywords: Direct spectrophotometric method; Cefpodoxime proxetil; Bromothymol blue; Ion-pair complex.  
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INTRODUCTION 
Cefpodoxime Proxetil (CEFP) is a third generation cephalosporin 
antibiotic indicated for the treatment of patients infected with 
susceptible strains of microorganisms which include a wide range of 
gram-positive and gram-negative bacteria. It is commonly used to 
treat acute otitis media, pharyngitis, and sinusitis. It is chemically 
described as (RS)-1(isopropoxycarbonyloxy) ethyl (+)-(6R, 7R)-7-
[2-(2-amino-4-thiazolyl)-2-[(Z) methoxyimino] acetamido]-3-
methoxy methyl- 8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-
carboxylate. The molecular formula of cefpodoxime proxetil is 
C21H27N5O9S2 and the molecular weight is 557.6 g/mol. It is freely 
soluble in dehydrated alcohol, acetonitrile, methanol and very 
slightly soluble in water [1-3], see Scheme 1.  
Bromothymol blue C27H28Br2O5S (BTB), acts as a weak acid in 
solution. It can thus be in protonated or deprotonated form, 
appearing yellow or blue, respectively. It is bluish green in neutral 
solution. The deprotonating of the neutral form results in a highly 
conjugated structure, accounting for the difference in color. An 
intermediate of the deprotonating mechanism is responsible for the 
greenish color in neutral solution, mol. mass 624.38 g [4], see 
scheme 2. Bromothymol blue has been used as a reagent to form ion 
pair complexes with drugs as diltiazem HCl [5]. 
 
 
Scheme 1: Chemical structure of cefpodoxime proxetil (CEFP) 
 
Scheme 2: Chemical structure of bromothymol blue 
(C27H28Br2O5S) 
 
A simple, sensitive, accurate and rapid UV-Vis spectrophotometric 
methods have been developed for the estimation of cefpodoxime 
proxetil in bulk drug and in pharmaceutical dosage form, which 
shows maximum absorbance at 415 and 425 nm for ion-pair 
complexes between cefpodoxime proxetil with bromocresol purple 
and bromocresol green, receptively, in acidic medium and the 
subsequent extraction of the ion-pair in chloroform [6].  
Various spectrophotometric methods [6-24] have been reported for 
the determination of cefpodoxime proxetil in pure as well as in 
dosage forms. Most spectrophotometric methods employ extraction 
procedures. In this case, the extracted complexes were into an 
organic solvent, which is immiscible with water, and the 
concentration of the resulting complex in the organic phase is 
determined spectrophotometrically. The complex extraction 
technique has some difficulties and inaccuracies due to incomplete 
extraction or the formation of emulsions between the hydrocarbon 
solvent and the basic compound-containing solution. In response to 
the problems resulting from the extraction of the complex, it is 
better to determine formed complex without extraction [25]. Also, 
none of the methods reported in the literature is based on the 
formation of a complex between BTB and CEFP. 
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In this study, a extraction-free spectrophotometric method for 
determination of CEFP through ion-pair complex formation with 
BTB was developed. 
MATERIALS AND METHODS 
Instruments and apparatus 
Spectrophotometric measurements were made in Spectro scan 80 
DV UV-VIS spectrophotometry with 1 cm quartz cells. An ultrasonic 
processor model Powersonic 405 was used to sonicate the sample 
solutions. The diluter pipette model DIP-1 (Shimadzu), having 100 μl 
sample syringe and five continuously adjustable pipettes covering a 
volume range from 20 to 5000 μl (model Piptman P, GILSON). 
Centrifuge (Centurion Scientific Ltd., Model: K2080-Manufactured in 
the United Kingdom) was used for the preparation of the 
experimental solutions. SARTORIUS TE64 electronic balance was 
used for weighing the samples. 
Reagents 
Cefpodoxime proxetil (96.138%) was supplied by Virchow group 
company (INDIA), its purity as cefpodoxime was (73.7%), (Mfg. 
07/2015, Exp. 07/2018). Bromothymol blue (97%) of analytical 
grade and chloroform of extra pure were from MERCK. All solvents 
and reagents were analytical grade chemicals. 
Stock standard solution of bromothymol blue (BTB) 1x10-2 mol/l 
Accurately weighed 160.92 mg of BTB was dissolved in chloroform 
into a volumetric flask (25 ml) and diluted up to mark with 
chloroform. 
Stock standard solution of CEFP 1x10-3 mol/l 
This solution was prepared by dissolving 14.50 mg of CEFP in 
chloroform into a volumetric flask (25 ml) and diluted up to mark 
with chloroform. 
Working standard solutions of CEFP 
The stock solution was further diluted daily just before the use to 
obtain working solutions of CEFP in the concentrations: 1.0, 2.0, 5.0, 
7.5, 10, 15, 20, 40, 60, 80 and 100 μM (0.5576, 1.1152, 2.788, 4.182, 
5.576, 8.364, 11.152, 22.304, 33.456, 44.608 and 55.760 μg/ml) by 
transferring different aliquots from stock standard solution: 10, 20, 
50, 75, 100, 150, 200, 400, 600, 800 and 1000 μl into 10 ml 
volumetric flasks, then 1 ml from stock standard solution of BTB was 
added, diluted to 10 ml with chloroform.  
Sample preparation  
Commercial formulations (as a tablet) were used for the analysis of 
CEFP. The pharmaceutical formulations subjected to the analytical 
procedure were:  
(1) Oracef tablets, ELSaad pharma, Aleppo–SYRIA, (Mfg. 09/2014, Exp. 
09/2018), each tablet contains 100 and 200 mg of cefpodoxime (CEF).  
(2) Oraxime tablets, Asia pharmaceutical industries, Aleppo–SYRIA, (Mfg. 
11/2014, Exp. 11/2017), each tablet contains 100 and 200 mg of CEF. 
(3) Oraluxe tablets, ALPHA. Aleppo pharmaceutical industries, 
Aleppo-SYRIA, (Mfg. 01/2015, Exp. 01/2018), each tablet contains 
100 and 200 mg of CEF.  
Stock solutions of pharmaceutical formulations 
20 tablets of each studied pharmaceutical formulation were weighed 
accurately, crushed to a fine powder and mixed well. An amount of 
the powder equivalent to the weight of one tablet was solved in 
chloroform using ultrasonic for 10 min, 20 ml of chloroform was 
added, filtered over a 25 ml flask and washed by the same solvent, 
then diluted to 25 ml with chloroform. This solution contains the 
follows: 4 and 8 mg/ml of CEF for all studied pharmaceutical 
formulations contain 100 and 200 mg/tab, respectively. 
Working solutions of pharmaceuticals 
Five solutions were prepared daily by diluting 100 and 50 µl from a 
stock solution of pharmaceutical formulations for contents: 100 and 
200 mg/tab, respectively. Then adding 1 ml from a stock standard 
solution of BTB and adjusting the volume up to 10 ml with 
chloroform (these solutions contain 40 μg/ml of CEF; test solutions). 
Procedure  
A solution (10 ml) containing an appropriate concentration of CEFP 
(or working solutions of pharmaceuticals) with appropriate amount 
of BTB in chloroform was ready for spectrophotometric 
measurement at λmax 422 nm.  
RESULTS AND DISCUSSION 
The different experimental parameters affecting the spectrophotometric 
determination of CEFP through ion-pair complex ([CEFP]:[BTB]2) 
formation with BTB in chloroform were studied in order to determine 
the optimal conditions for the determination of CEFP.  
Spectrophotometric results  
UV-Vis spectra of CEFP, BTB and the formed complexes CEFP: BTB 
solutions (using chloroform or 1x10-3M of BTB in chloroform as blank) 
were obtained. CEFP solutions do not absorb in the range 360-600 nm. 
BTB solutions have small absorption at λmax 410 nm (ε≈120  L. mol-1. 
cm-1). [CEFP]: [BTB] and [CEFP]:[BTB]2 complexes solutions have 
maximum absorption at λmax 422 nm, (ε for two complexes were 8100 
and 12600  L. mol-1. cm-1, respectively), see fig. 1.  
The effect of time and temperature  
The effect of time and temperature on the complex ([CEFP]:[BTB]2) 
formation was studied within the ranges 5-120 min and 15-30oC. It 
was found that the formed complex wasn't affected by time or 
temperature at those ranges.  
The effect of BTB concentration  
The effect of BTB concentration on complex ([CEFP]:[BTB]2) 
formation was investigated. It was observed that the absorbance of 
the formed complex increased coinciding with increasing the ratio of 
CBTB: CCEFP until the ratio (2:1), then slowly increased until the 
absorbance became a quasi-static at ratio more than 10. 
 
 
Fig. 1: UV-Vis spectra in chloroform of: 1-1.0x10-4 mol/l of BTB; 
2-1.0x10-4 mol/lof CEFP; 3-1.0x10-4 mol/l ion-pair complex 
[CEFP]:[BTB](1.0x10-4 mol/l of CEFP with 1.0x10-4 mol/l of 
BTB); 4-1.0x10-4 mol/l ion-pair complex [CEFP]:[BTB]2 (1.0x10-4 
mol/l of CEFP with 2.0x10-4 mol/l of BTB); 5, 6-1.0x10-4 mol/l 
ion-pair complex [CEFP]:[BTB]2 (1.0x10-4 mol/l of CEFP with 
1.0x10-3 mol/l of BTB); 1-5: Blank is chloroform; 6-Blank is 
1.0x10-3 mol/l of BTB, ℓ =1 cm 
 
Composition of CEFP: BTB complexes 
The composition of CEFP: BTB complexes were determined by the 
molar ratio method and Job's method of continuous variation. 
Molar ratio method  
The stoichiometry of CEFP: BTB complexes were studied by molar 
ratio method according to following equation: Amax= f([BTB]/[CEFP]) 
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at λmax 422 nm. It confirmed that the binding ratio of CEFP: BTB 
complexes are equal to (1:1 and 1:2); where the concentration of CEFP 
was constant (100 µM) and the concentrations of BTB changed from 0 to 
400 µM (fig. 2). The formation constant of the ion pair complexes 
[CEFP]:[BTB] and [CEFP]:[BTB]2 are 1.6x105 and 9.1x105, respectively. 
 
 
Fig. 2: Molar ratio method to calculate binding ratio of CEFP: 
BTB complexes at λ=422 nm ([CEFP]= 100 µM, blank is 
chloroform, ℓ =1 cm) 
 
Job’s method of continuous variation 
Continuous variation was utilized to check the composition of CEFP: 
BTB complexes at λmax 422 nm. The absorbance of the complexes 
were plotted against the mole fraction [BTB]/([CEFP]+[BTB]), 
where [CEFP]+[BTB]=200 µM. The plot reached maximum values at 
a mole fraction of 0.5 and 0.67, see fig. 3. This indicated complexes 
formation (CEFP: BTB) in the ratio of 1:1 and 1:2. The formation 
constant of the ion-pair complexes [CEFP]:[BTB] and [CEFP]:[BTB]2 
are 1.7x105 and 9.2x105, respectively.  
The optimum conditions for spectrophotometric determination of 
CEFP through ion-pair complex formation using BTB in chloroform 
are shown in table 1. 
 
Fig. 3: Job's method of continuous variation to calculate binding 
ratio of CEFP: BTB complexes at λ 422 nm 
([CEFP]+[BTB]=200 µM, blank is chloroform, ℓ =1 cm) 
 
Table 1: The optimum conditions for spectrophotometric, 
determination of CEFP by complexes formation with BTB in 
chloroform 
Parameters Operating modes 
Temperature of solution 20±5 oC 
CBTB: CCEFP, M ≥10 
Solvent chloroform 
Stability  12 h 
λmax of CEFP: BTB complexes 422 nm 
Light path (ℓ) 1.0 cm 
Spectra range 300–600 nm 
Mechanism of reaction 
Anionic dyes such as BTB form ion-pair complexes with the positively 
charged nitrogen-containing molecule. The colour of such dyes is due 
to the opening of lactoid ring and subsequent formation of the quinoid 
group (deprotonated). CEFP is protonated and forms yellow ion-pair 
complexes [CEFP]:[BTB] and [CEFP]:[BTB]2 with the dye. Each drug-
dye complex with two oppositely charged ions (positive on the drug 
and negative on the dye) behaves as a single unit held together by an 
electrostatic binding. The suggested mechanism of CEFP: BTB ion-pair 
complexes formation are shown in Scheme 3. 
 
 




The calibration curve of CEFP in pure form through complexation 
with BTB showed excellent linearity over the concentration range of 
1.0-100.0 µM (0.5576–55.760 μg/ml). Regression equations at λmax 
422 nm were as the follows:  
y=0.023x+0.0004 …………. (I) 
y=0.0227x+0.0035 ………… (II) 
For concentrations of CEFP 0.5576-11.152 μg/ml and 0.5576-55.760 
μg/ml, respectively, (fig. 4and5). The spectra characteristics of the 
method such as the molar absorptivity (ε), Beer's law, regression 
equation at λmax 422 nm (y=a. x+b); where y=absorbance, a=slope, 
x=concentration of CEFP in μM or μg/ml,b=intercept,the correlation 
coefficient, limit of detection (LOD) and limit of quantification (LOQ) 
are summarized in table 2.  
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Analytical results  
Spectrophotometric determination of CEFP through complexation with 
BTB in chloroform within optimal conditions using calibration curve was 
applied. The results, summarized in table 3, showed that the determined 
concentration of CEFP was rectilinear over the range of 1.0 to 100.0 μM 
or 0.5576 to 55.760 μg/ml with relative standard deviation (RSD) not 
more than 4.7%. The results obtained from the developed method have 
been compared with the official RP-HPLC method [26] and good 
agreement was observed between them (table 3). 
 
 
Fig. 4: Spectra of [CEFP]:[BTB]2 complex in present 1.0×10-3 M of 
BTB; where CCEFP as the follows: 0.5576, 1.1152, 2.788, 4.182, 
5.576, 8.364, 11.152, 22.304, 33.456, 44.608 and 55.760 μg/ml 
for curves (1-11) {Blank is BTB solution in chloroform 1x10-3M; 
ℓ = 1 cm} 
Method validation 
The developed method for estimation of CEFP has been validated in 
accordance with the International Conference on Harmonization 
guidelines (ICH) [27]. 
Specificity  
Specificity test determines the effect of excipients on the assay 
result. To determine the specificity of the method, standard solution 
of CEFP, commercial product solution and blank solutions were 
analyzed. The results of the tests proved that the components other 
than the drug did not produce any interfere. 
Linearity 
Several aliquots of a standard stock solution of CEFP were taken in 
different 10 ml volumetric flask and diluted up to the mark with 
chloroform such that their final concentrations were 0.5576-55.760 
μg/ml for CEFP. Absorbance was plotted against the corresponding 
concentrations to obtain the calibration graph, see fig. 5. Linearity 
equations obtained were y = 0.023x+0.0004 for the range 0.5576-
11.152 μg/ml (R2=0.9993) and y=0.0227x+0.0035 for the range 
0.5576-55.760 μg/ml (R2=0.9995). 
Precision and accuracy 
The precision and accuracy of proposed method were checked by 
recovery study by addition of standard drug solution to pre-analyzed 
sample solution at three different concentration levels (80%, 100% and 
120%) within the range of linearity for CEFP. The basic concentration 
level of sample solution selected for spiking of the CEFP standard 
solution was 11.152 μg/ml. The proposed method was validated 
statistically and through recovery studies and was successfully applied 
for the determination of CEFP in pure and dosage forms with average 
percent recoveries ranged from 99.0% to 101.4%, see table 4. 
 
 
Fig. 5: Calibration curve for determination of CEFP according to optimal conditions (at λmax 422 nm in present of 1×10-3 M of BTB) where 
CCEFP: 0.5576, 1.1152, 2.788, 4.182, 5.576, 8.364, 11.152, 22.304, 33.456, 44.608 and 55.760 μg/ml {Blank is BTB solution in chloroform 
1x10-3M; ℓ = 1 cm} 
 
Table 2: The parameters established for spectrophotometric determination of CEFP by complex formation with BTB in chloroform 
Parameters Operating values 
Molar absorptivity of [CEFP]:[BTB] complex (ε1 ), L. mol-1. cm-1 8.1x103 
Molar absorptivity of [CEFP]:[BTB]2 complex (ε2 ), L. mol-1. cm-1 1.26x104 
Regression equation for [CEFP]:[BTB]2 at λmax=422 nm (CCEFP= 0.5576-11.152 μg/ml):  
Slope 0.023 
Intercept 0.0004 
Correlation coefficient (R2) 0.9993 
Regression equation for [CEFP]:[BTB]2 at λmax=422 nm (CCEFP= 0.5576-55.760 μg/ml):  
Slope 0.0227 
Intercept 0.0035 
Correlation coefficient (R2) 0.9995 
Beer’s Law Limit, for CCEFP by μM 1-100 
Beer’s Law Limit, for CCEFP by µg/ml 0.5576-55.760 
RSD%  4.7 
LOD(3.3SD),  for CCEFP by µg/ml 0.088 
LOQ (10SD),  for CCEFP by µg/ml 0.27 
n=5, t=2.776. 
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Table 3: Spectrophotometric determination of CEFP through complex formation with BTB within optimal conditions using calibration 
curve in chloroform 















0.559 4.7 0.57±0.034 0.012 0.57±0.027 0.5576 
1.120 4.2 1.16±0.061 0.022 1.16±0.049 1.1152 
2.84 3.8 2.90±0.136 0.049 2.90±0.11 2.788 
4.16 3.6 4.11±0.183 0.066 4.11±0.15 4.182 
5.53 3.2 5.46±0.217 0.078 5.46±0.18 5.576 
8.31 3.1 8.24±0.316 0.114 8.24±0.26 8.364 
11.19 3.0 11.29±0.422  0.152 11.29±0.34 11.152 
22.31 2.9 22.31±0.802 0.289 22.31±0.65 22.304 
33.84 2.8 34.21±1.188 0.428 34.21±0.96 33.456 
44.92 2.7 45.31±1.518 0.547 45.31±1.22 44.608 
55.21 2.6 54.91±1.774 0.639 54.91±1.43 55.760 
* n=5, t= 2.776 
 
Table 4: Results of recovery studies 
Level % Recovery 
80% (n=5) 99.0 
100% (n=5) 101.2 
120% (n=5) 101.4 
 
Repeatability 
The repeatability was evaluated by performing 10 repeat 
measurements for 11.152 μg/ml of CEFP using the studied 
spectrophotometric method under the optimum conditions. The 
found amount of CEFP ( x ±SD) was 11.29±0.30 μg/ml and the 
percentage recovery was found to be 101.2±2.5 with RSD of 0.027. 
These values indicate that the proposed method has high 
repeatability for CEFP analysis.  
Sensitivity (limit of detection [LOD] and limit of quantitation 
[LOQ]) 
The sensitivity of the method was evaluated by determining the LOD 
and LOQ. The values of LOD and LOQ for CEFP are 0.088 and 0.27 
μg/ml, respectively. 
Robustness 
The robustness of the method adopted is demonstrated by the 
constancy of the absorbance with the deliberated minor change in the 
experimental parameters such as the change in the concentration of 
excipients, BTB (±5%), temperature (±5oC) and reaction time (30 
min). 
Applications 
The developed spectrophotometric method was applied to 
determine CEFP in some pharmaceutical preparations through 
complex formation by BTB in chloroform according to the optimal 
conditions. The amount (m) of CEFP in one tablet was calculated 
from the following relationship: m = h. m', where: m' is the amount 
of CEFP in tablet calculated according to the regression equation (II), 
h conversion factor is equal to 2.5 and 5.0 for pharmaceutical 
formulations contain 100 and 200 mg/tab, respectively. The results 
of quantitative analysis for CEFP in pharmaceutical preparations 
were summarized in Tables 5. The proposed method was simple, 
direct, specific and successfully applied to the determination of CEFP 
in pharmaceuticals without any interference from excipients. 
Average assay of marketed formulations ranged between 99.5 to 
103.2%. The results obtained by this method agree well with the 
contents stated on the labels and were validated by RP-HPLC 
method [26]. 
  
Table 5: Determination of CEFP, as cefpodoxime (CEF), in some Syrian pharmaceutical preparations using spectrophotometric method 
through complex formation with BTB in chloroform, λmax 422 nm 
Tablet dosage form Label claim  
of CEFP as CEF, mg/tab. 




Assay% * (Assay%), by RP-HPLC 
[26] 
Oracef 100 99.8±2.79 2.8 99.8 100.1 
200 202.0±5.46 2.7 101.0 101.2 
Oraxime  100 101.4±2.84 2.8 101.4 101.1 
200 203.0±5.48 2.7 101.5 101.7 
Oraluxe 100 103.2±2.86 2.8 103.2 103.5 
 200 199.0±5.37 2.7 99.5 99.4 
* n=5, Assay=(found mean/label claim)x100. 
 
CONCLUSION 
The developed spectrophotometric method is simple, direct 
(extraction-free) and cost-effective for the determination of CEFP in 
pure and tablet dosage forms. This method is based on formation of 
two ion-pair complexes between CEFP and BTB in chloroform 
([CEFP]:[BTB] and [CEFP]: [BTB]2). Beer’s law in the optimum 
experimental conditions using [CEFP]: [BTB]2 complexes is valid 
within a concentration range of 0.5576-55.760 μg/ml. The developed 
method is applied for the determination of CEFP in pure and its 
commercial tablets without any interference from excipients with the 
average assay of marketed formulations between 99.5 to 103.2%.  
This method was validated for specificity, linearity, precision and 
accuracy, repeatability, sensitivity (LOD and LOQ) and robustness 
with an average recovery of 99.0-101.4%. 
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